Home About Products Technology Investor Relations News Contact DRUGSORB-ATR The DrugSorb-ATR™ Antithrombotic Removal system is currently being evaluated for the ability to remove ticagrelor during cardiothoracic surgery and to reduce perioperative bleeding risk in the U.S. double-blind, randomized, controlled STAR-T (“Safe and Timely Antithrombotic Removal – Ticagrelor”) pivotal trial. The DrugSorb-ATR Antithrombotic removal system is based upon the same polymer technology as CytoSorb and is not yet FDA approved. Privacy Information Data Protection Disclaimer Contact CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders. Are you an Investor? CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world Are you a Healthcare Provider?